Skip to main content
Concord Biotech Limited logo

Concord Biotech Limited — Investor Relations & Filings

Ticker · CONCORDBIO ISIN · INE338H01029 LEI · 335800FBIZZTLAXLXZ73 BSE.NS Manufacturing
Open in API
Filings indexed 208 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS CONCORDBIO

About Concord Biotech Limited

https://concordbiotech.com/

Concord Biotech Limited is a research and development-driven company specializing in the production of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization focuses on niche therapeutic areas, including immunosuppressants, oncology, anti-fungals, and anti-infectives. It maintains a significant global presence, supplying products to regulated markets such as the United States, Europe, and Japan. Concord Biotech operates large-scale fermentation facilities and is recognized for its expertise in complex manufacturing processes. Its operations are vertically integrated, covering the entire value chain from strain development and fermentation to downstream processing and formulation. The company adheres to international quality standards, holding certifications from major regulatory bodies like the USFDA and EUGMP, ensuring the delivery of high-quality pharmaceutical solutions to its global clientele.

Recent filings

Filing Released Lang Actions
Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve the audited Standalone and ....
Regulatory Filings Classification · 88% confidence The document is an intimation to stock exchanges of an upcoming Board of Directors meeting to consider and approve financial results and other business. It does not contain the actual financial results (so it's not an interim or annual report), nor does it announce a governance change (no director appointments or resignations). It is a regulatory announcement pursuant to listing regulations, with general compliance information. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-23 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 75% confidence The document is a declaration by the promoter under SEBI’s Substantial Acquisition of Shares & Takeovers Regulations, stating shareholding percentage (44.08%) and no encumbrance. It is not a full report, earnings release, or board change, but a regulatory notification of a significant shareholding position under takeover rules. This aligns with “Major Shareholding Notification (MRQ).”
2026-05-18 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming no requests for dematerialization/rematerialization of shares for the quarter ended March 31, 2026. It is addressed to stock exchanges and signed by the company secretary and the registrar. The document length is about 3000 characters, and it primarily serves as a compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. This type of certificate is a regulatory compliance filing rather than an annual report, interim report, or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2026-04-08 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding an acquisition by Concord Biotech Limited. It references compliance with SEBI regulations (Listing Obligations and Disclosure Requirements) and provides detailed information about the acquisition of Celliimune Biotech Private Limited, including shareholding, consideration, and business purpose. The document is an acquisition announcement under regulatory disclosure requirements, not a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather the terms and details of the acquisition transaction. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2026-04-02 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter from Concord Biotech Limited addressed to stock exchanges notifying the closure of the trading window pursuant to SEBI regulations ahead of the announcement of audited financial results for the quarter and year ended 31st March 2026. It does not contain any financial data or results itself, nor does it include the actual audited financial results. Instead, it is an announcement related to compliance and insider trading restrictions before the financial results are declared. The document length is short (2620 characters) and it serves as a regulatory notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and regulatory announcements that do not fit other specific categories.
2026-03-27 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation to stock exchanges about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and explicitly states that the discussions will be based on publicly available information with no unpublished price sensitive information. The document is a notification about upcoming meetings rather than a report or transcript of the meetings themselves. It does not contain financial data, earnings, or detailed presentations. Therefore, it fits the category of Investor Presentation (IP) updates or announcements. However, since it is only an intimation of the schedule of meetings and not the presentation itself, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories. The document length is short (2263 characters), and it is an announcement rather than a report or transcript. Hence, the classification is Regulatory Filings (RNS) with high confidence.
2026-02-26 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.